ArticlePersonalized medicine2016
Integration of genetic and epigenetic markers for risk stratification: opportunities and challenges.
Article in Personalized medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Blood-based DNA methylation markers for lung cancer prediction.BMJ oncology · 2024Article
- Susceptibility to hypertension based onFrontiers in cardiovascular medicine · 2023Article
- Exploring the Ethics of Implementation of Epigenomics Technologies in Cancer Screening: A Focus Group Study.Epigenetics insights · 2021Article
- Epigenome-wide association study reveals CpG sites related to COG of neuroblastoma.Bioscience reports · 2020Article
- Analysis of DNA methylation in endometrial biopsies to predict risk of endometrial cancer.Gynecologic oncology · 2020Article
- Polygenic risk-stratified screening for cancer: Responsibilization in public health genomics.Social studies of science · 2019Article
- Autonomy Challenges in Epigenetic Risk-Stratified Cancer Screening: How Can Patient Decision Aids Support Informed Consent?Journal of personalized medicine · 2019Review
- Epigenetic Changes in the Pathogenesis of Rheumatoid Arthritis.Frontiers in genetics · 2019Review
- Article
- Epigenome-based cancer risk prediction: rationale, opportunities and challenges.Nature reviews. Clinical oncology · 2018Review
- Ethical, Legal, and Regulatory Issues for the Implementation of Omics-Based Risk Prediction of Women's Cancer: Points to Consider.Public health genomics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Common genetic susceptibility variants could be used for risk stratification in risk-tailored cancer screening and prevention programmes. Combining genetic variants with environmental risk factors would improve risk stratification. Epigenetic changes are surrogate markers of environmental exposures during individual's lifetime. Integrating epigenetic markers, in lieu of environmental exposure data, with genetic markers would potentially improve risk stratification. Epigenetic changes are reversible and acquired gradually, providing potentials for prevention and early detection strategies. The epigenetic changes are tissue-specific and stage-of-development-specific, raising challenges in choice of sample and timing for evaluation of cancer-associated changes. The Horizon 2020 funded research programme, FORECEE, using empirical data, will investigate the value of integration of epigenomics with genomics for risk prediction and prevention of women-specific cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.